What are the side effects of mirikizumab? What adverse reactions may occur when using it?

Milizumab is a new type of immunosuppressant that is an IL-23 inhibitor and is used to treat autoimmune diseases such as moderately to severely active ulcerative colitis. Although militizumab has significant efficacy in controlling disease symptoms and reducing inflammation, like all drugs, it may also cause a series of side effects and adverse reactions during use, and patients need to pay special attention when using it.

One of the common side effects of milizumab is infectious diseases. Because of its ability to suppress the immune system, patients may be more susceptible to bacterial, viral, and fungal infections, especially early in treatment. For example, upper respiratory tract infections, urinary tract infections, skin infections, etc. may occur. In the most severe cases, militizumab may cause serious opportunistic infections such as tuberculosis, pneumonia, or herpes zoster. To prevent these infections, patients taking militizumab should be regularly screened for infections and tested for potential infections such as tuberculosis before using the drug.

In addition, militizumab may also cause adverse reactions in the digestive system. Patients may experience gastrointestinal symptoms such as diarrhea, abdominal pain, and nausea after taking militizumab. These symptoms are usually mild, but in some cases treatment may need to be adjusted or symptomatic treatment given. Especially for patients who already have ulcerative colitis, the gastrointestinal side effects caused by drugs may overlap with the symptoms of the disease itself. Therefore, patients should communicate closely with their doctors during medication and observe whether there are signs of aggravation.

In addition, militizumab may cause allergic reactions. Although allergic reactions are relatively rare, it cannot be ruled out that some patients may experience allergic symptoms when using the drug, such as rash, difficulty breathing, facial swelling, etc. If patients develop these symptoms while taking militizumab, they should stop taking the drug immediately and seek emergency medical attention. The risk of anaphylaxis, although not high, is still an aspect that requires caution when using militizumab.

Militizumab may also affect patients' liver function. In some patients, long-term use of militizumab may lead to elevated liver enzymes, and liver damage sometimes manifests as jaundice, loss of appetite, fatigue and other symptoms. Patients should regularly monitor liver function during treatment to ensure it is within the normal range. If significant liver function abnormalities occur, treatment may need to be suspended or discontinued and appropriate therapeutic intervention implemented.

In summary, militizumab, as a biological agent, has shown significant effects in the treatment of ulcerative colitis and other diseases, but it is also accompanied by some potential adverse reactions. Patients should pay close attention to infections, gastrointestinal symptoms, allergic reactions, and changes in liver function when taking militizumab. Regular physical examination and monitoring can help detect and deal with side effects in a timely manner and ensure the safety and effectiveness of treatment. During use, patients should keep in close contact with their doctors and adjust the medication plan according to individual conditions to maximize the therapeutic effect and reduce the occurrence of adverse reactions.

Reference materials:https://omvoh.lilly.com/